PBLS logo

Parabilis Medicines, Inc.

PBLS
Healthcare|Biotechnology|US
$28.53
+0.65 (+2.33%)
Tangible Book / Share
$36.24
Cash / Share
$38.77

Financials

Financial Snapshot

Market Cap
$3.48B
Enterprise Value
$2.44B
Revenue (TTM)
$148.0K
Net Income (TTM)
-$170.9M
Cash & Investments
$1.12B
Net Cash
$1.07B
Free Cash Flow (TTM)
-$119.1M
Operating CF (TTM)
-$118.1M
Debt/Equity
0.05

Cash Runway & Burn Rate

Cash on Hand
$1.12B
Quarterly Burn
$29.5M
Monthly Burn
$9.8M
Est. Runway
~38.0 quarters
MetricTrend20242025TTM
Cash & Investments
$88.0M$27.7M$1.12B
Operating Cash Flow
-$103.6M-$123.7M-$118.1M
Free Cash Flow
-$104.5M-$124.0M-$119.1M
Capital Expenditure
-$879.0K-$306.0K-$1.1M
Financing Cash Flow
$78.1M$64.4M$1.21B

R&D Spending

R&D (TTM)
$141.2M
R&D Intensity
95379.1%
R&D Growth vs Prior
+12.4%
MetricTrend20242025TTM
Revenue
$0.00$0.00$148.0K
R&D Expense
$100.8M$125.6M$141.2M
R&D % of Revenue——95379.1%
SG&A
$25.3M$26.5M$33.5M

Income Statement

MetricTrend20242025TTM
Revenue
$0.00$0.00$148.0K
Cost of Revenue
$0.00$0.00$618.0K
Gross Profit
$0.00$0.00-$470.0K
R&D
$100.8M$125.6M$141.2M
SG&A
$25.3M$26.5M$33.5M
Operating Income
-$126.1M-$152.1M-$175.1M
Interest Expense
$1.5M$1.5M$1.3M
Pretax Income
-$117.9M-$145.9M-$170.9M
Net Income
-$117.9M-$145.9M-$170.9M
EPS (Diluted)
-83.48-92.40-61.10
EBITDA
-$114.3M-$141.9M-$169.3M
Shares Out. (M)
1.932.0228.91

Balance Sheet

MetricTrend20242025TTM
Cash & Equivalents
$47.3M$27.7M$1.09B
Short-Term Investments
$40.7M$0.00$33.6M
Total Current Assets
$92.2M$29.4M$1.13B
Total Assets
$149.3M$80.8M$1.18B
Total Current Liabilities
$32.4M$56.8M$62.8M
Long-Term Debt
$12.8M$0.00$0.00
Total Liabilities
$92.8M$97.3M$127.5M
Stockholders' Equity
$56.4M-$16.5M$1.05B
Retained Earnings
-$395.6M-$541.5M-$639.3M

Cash Flow Statement

MetricTrend20242025TTM
Operating Cash Flow
-$103.6M-$123.7M-$118.1M
Capital Expenditure
-$879.0K-$306.0K-$1.1M
Free Cash Flow
-$104.5M-$124.0M-$119.1M
Investing Cash Flow
$30.2M$39.8M-$3.2M
Financing Cash Flow
$78.1M$64.4M$1.21B
Issuance of Stock
$78.1M$67.5M$1.17B
Repurchase of Stock
$0.00$0.00$0.00
Net Debt Issuance
$0.00-$3.1M-$8.1M
Stock Based Comp.
$4.3M$3.3M$6.6M
Net Change in Cash
$4.7M-$19.6M$1.09B

Dilution Tracker

Shares Outstanding
122M
5-Year Share Growth
+4.6%
Stock Issuance (TTM)
$1.17B
MetricTrend20242025TTM
Shares Out. (M)
1.932.0228.91
Change vs Prior %
—4.6%1328.9%
Stock Issuance
$78.1M$67.5M$1.17B
Stock Repurchase
$0.00$0.00$0.00
Stock Based Comp.
$4.3M$3.3M$6.6M

Margins & Profitability

MetricTrend20242025TTM
Gross Margin %——-317.6%
Operating Margin %——-118310.8%
Net Margin %——-115483.1%
EBITDA Margin %——-114360.1%
FCF Margin %——-80500.7%
ROE %
-208.9%882.9%-15.1%
ROA %
-79.0%-180.5%-8.3%
ROIC %
-99.9%-338.6%-8.7%
R&D / Revenue %——95379.1%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend20242025
Revenue
0.0%0.0%
Gross Profit
0.0%0.0%
Operating Income
0.0%-20.6%
Net Income
0.0%-23.7%
EPS (Diluted)
0.0%-10.7%
Operating Cash Flow
0.0%-19.4%
Free Cash Flow
0.0%-18.7%
R&D Expense
0.0%24.6%
SG&A Expense
0.0%4.7%
Total Assets
0.0%-45.9%
Book Value / Share
0.0%-128.0%
Debt
0.0%-11.3%
Diluted Shares
0.0%4.6%

Valuation

P/E (TTM)At Loss
P/S23508.73
P/B0.79
EV/EBITDAAt Loss
EV/Revenue16484.75
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$36.24
Net Current Assets / Share
$8.18
Graham Net-Net
$34.36
Cash / Share
$38.77
MetricTrend20242025TTM
P/E Ratio
-0.24-0.22-0.77
P/S Ratio
0.000.0023508.73
P/B Ratio
0.69-2.450.79
EV/EBITDA
-0.50-0.50-25.39
EV/Revenue
0.000.0016484.75

Analyst Estimates & Quality

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$1.6M$9.0M$7.0M
Net Income-$5.3M-$3.6M-$4.0M
EPS$-2.60$-1.78$-1.97
# Analysts (EPS)331